LXRX Earnings Lexicon Pharmaceuticals, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–31 of 31
| Q2 2026 | 2026-06-30 | -0.08 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | 0.00 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | -0.14 | 2026-03-05 | 10-K |
| Q3 2025 | 2025-09-30 | -0.10 | 2025-11-06 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.06 | 2026-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.07 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -0.63 | 2026-03-05 | 10-K |
| Q3 2025 | 2024-09-30 | -0.54 | 2025-11-06 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.37 | 2025-08-06 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.20 | 2025-05-14 | 10-Q |
| FY 2025 | 2023-12-31 | -0.80 | 2026-03-05 | 10-K |
| Q3 2024 | 2023-09-30 | -0.60 | 2024-11-13 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.39 | 2024-08-02 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.17 | 2024-05-02 | 10-Q |
| FY 2024 | 2022-12-31 | -0.62 | 2025-03-07 | 10-K |
| Q3 2023 | 2022-09-30 | -0.45 | 2023-11-08 | 10-Q |
| FY 2023 | 2021-12-31 | -0.60 | 2024-03-25 | 10-K |
| Q3 2021 | 2021-09-30 | -0.43 | 2021-11-09 | 10-Q |
| FY 2019 | 2020-12-31 | -0.53 | 2022-03-10 | 10-K |
| Q3 2021 | 2020-09-30 | -0.50 | 2021-11-09 | 10-Q |
| FY 2019 | 2019-12-31 | 1.16 | 2022-03-10 | 10-K |
| Q3 2020 | 2019-09-30 | 1.59 | 2020-10-30 | 10-Q |
| FY 2019 | 2019-06-30 | -0.22 | 2020-03-12 | 10-K |
| FY 2019 | 2019-03-31 | -0.21 | 2020-03-12 | 10-K |
| FY 2019 | 2018-12-31 | -1.14 | 2021-03-12 | 10-K |
| Q3 2019 | 2018-09-30 | -0.98 | 2019-11-07 | 10-Q |
| FY 2019 | 2017-12-31 | -1.17 | 2020-03-12 | 10-K |
| FY 2016 | 2015-12-31 | 0.76 | 2017-03-06 | 10-K |
| FY 2016 | 2015-09-30 | -0.34 | 2017-03-06 | 10-K |
| FY 2016 | 2015-06-30 | -0.27 | 2017-03-06 | 10-K |
| FY 2016 | 2015-03-31 | -0.27 | 2017-03-06 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.